Prelude Therapeutics
58 articles about Prelude Therapeutics
-
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
2/9/2023
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.
-
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
11/14/2022
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent clinical and development pipeline progress.
-
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
10/18/2022
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that the U.S. Food and Drug Administration, cleared the company to proceed with a Phase 1 study under its Investigational New Drug Application for PRT3789, a first-in-class potent and selective SMARCA2 protein degrader.
-
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
8/9/2022
Prelude Therapeutics Incorporated today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent clinical and development pipeline progress.
-
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
5/10/2022
Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress.
-
PreludeDx™ Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio
3/22/2022
Prelude Corporation, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors.
-
Prelude Therapeutics Reports Full Year 2021 Financial Results
3/16/2022
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2021.
-
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
3/11/2022
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in Miami, FL on Thursday, March 17, 2022 at 9:00 a.m. ET.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting
3/9/2022
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today provided a clinical update on its diverse and growing pipeline and announced that new preclinical data have been accepted for presentation at the upcoming 2022 American Association for Cancer Research (AACR) Annual Meeting being held April 8-13 in New Orleans, Louisiana.
-
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
3/9/2022
Prelude Therapeutics Incorporated a clinical-stage precision oncology company, announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022.
-
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/11/2022
Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18 at 1:40 p.m. ET.
-
Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
1/4/2022
Prelude Therapeutics Inc. will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13, 2022.
-
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference
11/23/2021
Prelude Therapeutics Inc. today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place on Wednesday, December 1, 2021 at 9:15 am ET.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
11/12/2021
Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent clinical and development pipeline progress.
-
Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 InhibitorPhase 1 Clinical Trial in Patients with Selected Solid Tumors Anticipated to Begin by Year-End
11/8/2021
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its precision oncology candidate, PRT2527, which is designed to be a potent and selective CDK9 inhibitor.
-
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
10/7/2021
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of data from multiple pipeline programs, including the dose escalation portions of the Company’s ongoing Phase 1 trials of lead oral protein arginine methyltransferase 5 (PRMT5) inhibitors PRT543 and PRT811.
-
Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences
9/2/2021
Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced that members of its management team will participate in two upcoming virtual investor conferences.